Companies Will
Partner to Provide Complete Supply Chain Solutions for
the Life Science and Biopharmaceutical Industries
NASHVILLE, Tenn., Nov. 27,
2023 /PRNewswire/ -- Cryoport Inc. (Nasdaq:
CYRX) ("Cryoport" or the "Company"), a leading global provider of
innovative products and services to the fast-growing cell and gene
therapy industry enabling the future of medicine for a new era of
life sciences, and NIPPON EXPRESS HOLDINGS, INC. ("Nippon
Express"), global logistics company, today announced a strategic
partnership to provide temperature-controlled supply chain services
for the life sciences industry on a global basis.
Cryoport and Nippon Express will partner to design and implement
comprehensive supply chain solutions to support each other's
business efforts. The partnership will cover globally. This
relationship brings together Nippon Express' industry-leading
global logistics, with Cryoport Systems' fully integrated system,
processes and equipment including its shipping packages, data
solutions, biostorage and bioservices, and the ability to provide
complete cell and gene therapy support services from upstream
biomaterial collection to final delivery for dosing.
Jerrell Shelton, Chief Executive
Officer of Cryoport, commented, "This partnership builds on our
growing presence globally and bolsters our ability to service
customers by benefiting from Nippon Express' industry-leading
global network. As an organization, Cryoport is committed to
enhancing its logistics solutions and adding new capabilities to
support the life sciences. Today's collaboration is the latest in a
series of strategic partnerships to build greater value for our
clients as we fulfill this mission."
Nippon Express added, "We are excited to partner with Cryoport
Systems, a recognized leader in providing temperature-controlled
supply chain solutions. Working together we can leverage each
other's complementary strengths to meet the rapidly growing demand
in the life sciences and biopharmaceutical industries for a
complete supply chain solution."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global provider of
innovative products and services to the fast-growing Cell &
Gene Therapy industry - enabling the future of medicine for a new
era of life sciences. With 48 strategic locations covering the
Americas, EMEA (Europe, the
Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform
provides mission-critical bio-logistics, bio-storage,
bio-processing, and cryogenic systems to the life sciences markets
worldwide.
For more information, visit www.cryoport.com or follow
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
About Nippon Express
Since its establishment in 1937, the NX Group has expanded its
business from Japan to the world
by contributing to the development of societies, linking people,
companies, and communities through logistics. It has 739 bases in
312 cities in 49 countries and regions worldwide (as of the end of
September 2023) and is
expanding. It has a long-term vision of becoming "a logistics
company with a strong presence in the global market" in 2037, the
100th anniversary of its founding.
Forward-Looking Statements
Statements in
this press release which are not purely historical, including
statements regarding the Company's intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future, are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, those
related to the Company's industry, business, long-term growth
prospects, including expected growth in all of the Company's
markets, plans, strategies, acquisitions, future financial results
and financial condition, such as the Company's outlook and guidance
for full year 2023 revenue and the related assumptions and factors
expected to drive revenue, projected growth trends in the markets
in which the Company operates, the Company's plans and expectations
regarding the launch of new products and services, such as the
expected timing and benefits of such products and services
launches, the Company's plans to further strengthen its business
and continue to position itself for long-term and profitable growth
in the cell and gene therapy industry, and anticipated regulatory
filings or approvals with respect to the products of the Company's
clients. It is important to note that the Company's actual results
could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ
materially include, but are not limited to, risks and uncertainties
associated with the effect of changing economic conditions,
including as a result of the COVID-19 pandemic and its variants,
supply chain constraints, inflationary pressures, the ongoing war
between Russia and Ukraine and the effects of foreign currency
fluctuations, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors discussed in the Company's SEC reports,
including in the "Risk Factors" section of its most recently filed
periodic reports on Form 10-K and Form 10-Q, as well as in its
subsequent filings with the SEC. The forward-looking statements
contained in this press release speak only as of the date hereof
and the Company cautions investors not to place undue reliance on
these forward-looking statements. Except as required by law, the
Company disclaims any obligation, and does not undertake to update
or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-and-nippon-express-holdings-form-global-strategic-partnership-for-temperature-controlled-supply-chain-services-301995552.html
SOURCE Cryoport, Inc.